Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A with or without other anticancer therapies in selected advanced solid tumors
NL-OMON58969Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vibostolimab + pembrolizumab, pembrolizumab and vibostolimab in Cervical Cancer (CC), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC) and 8 more (3 arms), sponsored by Merck & Co. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)biliary canceresophageal cancer
Beyond the preview
Go deeper on NL-OMON58969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58969.